Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

Executive Summary

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
Advertisement

Related Content

Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers
Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer
Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Advertisement
UsernamePublicRestriction

Register

PS044049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel